Analysts at Beaufort Securities assumed coverage on shares of Nuformix (LON:NFX) in a report issued on Friday. The firm set a “speculative buy” rating and a GBX 5 ($0.07) price target on the stock. Beaufort Securities’ price objective points to a potential upside of 25.00% from the stock’s previous close.
Shares of Nuformix (NFX) opened at GBX 4 ($0.05) on Friday. Nuformix has a fifty-two week low of GBX 1.75 ($0.02) and a fifty-two week high of GBX 4.70 ($0.06).
Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002.
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.